경구 생물학적 제제 및 바이오시밀러 시장 보고서(2026년)

Biologics are drugs derived from living cells using highly sophisticated technologies, whereas biosimilars are developed to act similarly to biologics but are not exact replicas. Oral biologics and biosimilars include biologic and biosimilar drugs administered orally for the targeted treatment of conditions such as Alzheimer's, multiple sclerosis, HIV/AIDS, and other serious diseases. They are also used to manage chronic illnesses like diabetes, arthritis, and cancer.

The main therapy types of oral biologics and biosimilar lymphocytes are modulators, interleukin inhibitors, tumor necrosis factor-alpha inhibitors, immunostimulants, GPCR modulators, and others. Interleukin inhibitors are immunosuppressive drugs that block the activity of interleukins. These therapies address diseases including asthma, Crohn's disease, cancer, infectious diseases, autoimmune disorders, and others, using molecular types such as vaccines, proteins and peptides, monoclonal antibodies, and additional therapeutics. They are distributed through hospital pharmacies, retail pharmacies, and online channels.

Tariffs have impacted the oral biologics and biosimilars market by increasing the cost of imported active pharmaceutical ingredients, proteins, and peptides used in oral biologic formulations. Segments such as monoclonal antibodies and protein-based therapies are most affected, particularly in North America and Europe where imports dominate. This has led to higher treatment costs and potential delays in product availability. On the positive side, tariffs have encouraged local manufacturing, innovation in cost-effective oral formulations, and diversification of the supply chain.

The oral biologics & biosimilars market research report is one of a series of new reports from The Business Research Company that provides oral biologics & biosimilars market statistics, including oral biologics & biosimilars industry global market size, regional shares, competitors with a oral biologics & biosimilars market share, detailed oral biologics & biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oral biologics & biosimilars industry. This oral biologics & biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oral biologics & biosimilars market size has grown exponentially in recent years. It will grow from $9.37 billion in 2025 to $11.28 billion in 2026 at a compound annual growth rate (CAGR) of 20.3%. The growth in the historic period can be attributed to limited availability of oral biologics, high cost of biologic therapies, reliance on injectable formulations, increasing prevalence of chronic diseases, growing hospital and retail pharmacy networks.

The oral biologics & biosimilars market size is expected to see exponential growth in the next few years. It will grow to $24.69 billion in 2030 at a compound annual growth rate (CAGR) of 21.6%. The growth in the forecast period can be attributed to development of biosimilars and combination therapies, expansion of oral biologics pipelines, increasing patient preference for oral medications, rising adoption of digital adherence tools, growing government support and reimbursement policies. Major trends in the forecast period include rising adoption of oral biologics and biosimilars for chronic diseases, growth in targeted therapies for diabetes, arthritis, and cancer, increasing development of monoclonal antibody-based oral treatments, expansion of hospital, retail, and online pharmacy distribution channels, focus on patient adherence and personalized treatment plans.

The mounting prevalence of chronic diseases is poised to boost the oral biologics and biosimilars market ahead. Chronic diseases are persistent health conditions that develop gradually, including diabetes, heart disorders, and lung issues. Their surge largely stems from inactive lifestyles, where extended lack of movement raises risks of obesity, cardiovascular problems, type 2 diabetes, and select cancers. Oral biologics and biosimilars advance this area by delivering convenient, economical, patient-friendly options for ongoing chronic care. For instance, in January 2023, the Centers for Disease Control and Prevention (CDC), a US-based federal agency, reported 76.4% of U.S. adults-about 194 million-had at least one chronic condition that year, with rates hitting 59.5% in young adults, 78.4% in midlife adults, and 93.0% in older adults. Therefore, the rising prevalence of chronic diseases is driving the growth of the oral biologics and biosimilar market.

Prominent companies in the oral biologics & biosimilars market are pioneering tailored smart capsule services to refine oral biologic delivery, lift bioavailability, and offer easier dosing over injections. Smart capsules employ specialized coatings, timed-release systems, or shielding agents to protect biologics from gut breakdown and pinpoint intestinal uptake, presenting a needle-free path with better compliance. For instance, in December 2024, Lonza Group AG, a Switzerland-based contract development and manufacturing organization (CDMO), rolled out a custom smart capsule development service for oral biologics. It covers bespoke formulation crafting, excipient picking, and capsule design for biologic stability and precise release; it works by boosting fragile biomolecule absorption while preserving potency; highlights feature full-cycle aid from idea to preclinicals, multi-modality fit (proteins, peptides, nucleic acids), and scalable production; uses include oral monoclonal antibodies, peptides, and vaccines; advantages span patient ease, less injection dependence, stronger adherence, and quicker timelines for oral therapies.

In September 2023, Biocon Limited, an India-based pharmaceutical company, acquired Eywa Pharma Inc. for $7.7 million. The acquisition additionally enables businesses to diversify their manufacturing infrastructure, ensuring supply continuity and providing oral solid dosage capacities for new products ahead of schedule. Eywa Pharma Inc. is a US-based pharmaceutical company that specializes in oral biologics and biosimilars.

Major companies operating in the oral biologics & biosimilars market are Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oral biologics & biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oral biologics and biosimilar market consists of sales of receptor modulators, biological agents, and biosimilar lymphocytes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Biologics & Biosimilars Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses oral biologics & biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral biologics & biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oral biologics & biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Therapy: Lymphocyte Modulators; Immunostimulants; GPCR Modulators; Other Therapies
• 2) By Disease: Diabetes; Arthritis and Crohn's Disease; Cancer; Infectious Disease; Other Autoimmune Disease; Other Diseases
• 3) By Molecule Type: Vaccines; Proteins and Peptides; Other Molecule Types
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Lymphocyte Modulators: T-Cell Modulators; B-Cell Modulators; Sphingosine-1-Phosphate Receptor Modulators
• 2) By Immunostimulants: Cytokines; Immune Checkpoint Inhibitors; Adjuvants
• 3) By GPCR Modulators: Agonists; Antagonists; Biased Ligands
• 4) By Other Therapies: Cell-Based Therapies; Gene Therapies; Combination Therapies
• Companies Mentioned: Merck & Co. Inc.; GlaxoSmithKline; Novo Nordisk; BiosanaPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Sanofi; Microgen; Geropharm; Valenta; NovaMedica; SynBio; Roche; Rani Therapeutics; Eli Lilly and Company; Emisphere Technologies Inc.; Enteris BioPharma; Allena Pharmaceuticals; Abbvie; Johnson & Johnson; Pfizer Inc.; Biogen Inc.; Ache; Eurofarma; Teva Pharmaceuticals; Oramed Pharmaceuticals; Entera Bio; Julphar; Hikma Pharmaceuticals; Altis Biologics; Cipla Medpro South Africa; Genzyme
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Oral Biologics & Biosimilars Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Oral Biologics & Biosimilars Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Oral Biologics & Biosimilars Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Oral Biologics & Biosimilars Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Oral Biologics And Biosimilars For Chronic Diseases
  • 4.2.2 Growth In Targeted Therapies For Diabetes, Arthritis, And Cancer
  • 4.2.3 Increasing Development Of Monoclonal Antibody-Based Oral Treatments
  • 4.2.4 Expansion Of Hospital, Retail, And Online Pharmacy Distribution Channels
  • 4.2.5 Focus On Patient Adherence And Personalized Treatment Plans

5. Oral Biologics & Biosimilars Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Retail Pharmacies
• 5.3 Online Pharmacies
• 5.4 Specialty Clinics
• 5.5 Biotechnology And Pharmaceutical Companies

6. Oral Biologics & Biosimilars Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Oral Biologics & Biosimilars Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Oral Biologics & Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Oral Biologics & Biosimilars Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Oral Biologics & Biosimilars Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Oral Biologics & Biosimilars Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Oral Biologics & Biosimilars Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Oral Biologics & Biosimilars Market Segmentation

• 9.1. Global Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Lymphocyte Modulators, Immunostimulants, GPCR Modulators, Other Therapies
• 9.2. Global Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Diabetes, Arthritis and Crohn's Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases
• 9.3. Global Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Vaccines, Proteins and Peptides, Other Molecule Types
• 9.4. Global Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• 9.5. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of Lymphocyte Modulators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators
• 9.6. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of Immunostimulants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cytokines, Immune Checkpoint Inhibitors, Adjuvants
• 9.7. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of GPCR Modulators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Agonists, Antagonists, Biased Ligands
• 9.8. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of Other Therapies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cell-Based Therapies, Gene Therapies, Combination Therapies

10. Oral Biologics & Biosimilars Market Regional And Country Analysis

• 10.1. Global Oral Biologics & Biosimilars Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Oral Biologics & Biosimilars Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Oral Biologics & Biosimilars Market

• 11.1. Asia-Pacific Oral Biologics & Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Oral Biologics & Biosimilars Market

• 12.1. China Oral Biologics & Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Oral Biologics & Biosimilars Market

• 13.1. India Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Oral Biologics & Biosimilars Market

• 14.1. Japan Oral Biologics & Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Oral Biologics & Biosimilars Market

• 15.1. Australia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Oral Biologics & Biosimilars Market

• 16.1. Indonesia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Oral Biologics & Biosimilars Market

• 17.1. South Korea Oral Biologics & Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Oral Biologics & Biosimilars Market

• 18.1. Taiwan Oral Biologics & Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Oral Biologics & Biosimilars Market

• 19.1. South East Asia Oral Biologics & Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Oral Biologics & Biosimilars Market

• 20.1. Western Europe Oral Biologics & Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Oral Biologics & Biosimilars Market

• 21.1. UK Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Oral Biologics & Biosimilars Market

• 22.1. Germany Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Oral Biologics & Biosimilars Market

• 23.1. France Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Oral Biologics & Biosimilars Market

• 24.1. Italy Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Oral Biologics & Biosimilars Market

• 25.1. Spain Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Oral Biologics & Biosimilars Market

• 26.1. Eastern Europe Oral Biologics & Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Oral Biologics & Biosimilars Market

• 27.1. Russia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Oral Biologics & Biosimilars Market

• 28.1. North America Oral Biologics & Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Oral Biologics & Biosimilars Market

• 29.1. USA Oral Biologics & Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Oral Biologics & Biosimilars Market

• 30.1. Canada Oral Biologics & Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Oral Biologics & Biosimilars Market

• 31.1. South America Oral Biologics & Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Oral Biologics & Biosimilars Market

• 32.1. Brazil Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Oral Biologics & Biosimilars Market

• 33.1. Middle East Oral Biologics & Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Oral Biologics & Biosimilars Market

• 34.1. Africa Oral Biologics & Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Oral Biologics & Biosimilars Market, Segmentation By Therapy, Segmentation By Disease, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Oral Biologics & Biosimilars Market Regulatory and Investment Landscape

36. Oral Biologics & Biosimilars Market Competitive Landscape And Company Profiles

• 36.1. Oral Biologics & Biosimilars Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Oral Biologics & Biosimilars Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Oral Biologics & Biosimilars Market Company Profiles
  • 36.3.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. GlaxoSmithKline Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Novo Nordisk Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. BiosanaPharma Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. AstraZeneca Overview, Products and Services, Strategy and Financial Analysis

37. Oral Biologics & Biosimilars Market Other Major And Innovative Companies

• Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, AbbVie

38. Global Oral Biologics & Biosimilars Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Oral Biologics & Biosimilars Market

40. Oral Biologics & Biosimilars Market High Potential Countries, Segments and Strategies

• 40.1 Oral Biologics & Biosimilars Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Oral Biologics & Biosimilars Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Oral Biologics & Biosimilars Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer